Reply to S. Al Hadidi et al
- PMID: 36626698
- DOI: 10.1200/JCO.22.02438
Reply to S. Al Hadidi et al
Conflict of interest statement
Comment on
-
Overall Survival Analysis of the Use of Elotuzumab in ELOQUENT-3 Trial.J Clin Oncol. 2023 Mar 20;41(9):1788. doi: 10.1200/JCO.22.02098. Epub 2023 Jan 10. J Clin Oncol. 2023. PMID: 36626704 No abstract available.
Publication types
LinkOut - more resources
Full Text Sources
